CA3113094A1 - Compositions et methodes de prevention et/ou de traitement de la covid-19 - Google Patents

Compositions et methodes de prevention et/ou de traitement de la covid-19 Download PDF

Info

Publication number
CA3113094A1
CA3113094A1 CA3113094A CA3113094A CA3113094A1 CA 3113094 A1 CA3113094 A1 CA 3113094A1 CA 3113094 A CA3113094 A CA 3113094A CA 3113094 A CA3113094 A CA 3113094A CA 3113094 A1 CA3113094 A1 CA 3113094A1
Authority
CA
Canada
Prior art keywords
nucleic acid
acid vaccine
covid
protein
sars
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3113094A
Other languages
English (en)
Inventor
Eric G. Marcusson
Jumai Adeola Abioye
Natalia Martin Orozco
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Providence Therapeutics Holdings Inc
Original Assignee
Providence Therapeutics Holdings Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CA3096009A external-priority patent/CA3096009A1/fr
Application filed by Providence Therapeutics Holdings Inc filed Critical Providence Therapeutics Holdings Inc
Priority to CA3116284A priority Critical patent/CA3116284A1/fr
Priority to CA3116932A priority patent/CA3116932A1/fr
Priority to CA3118329A priority patent/CA3118329A1/fr
Priority to CA3128078A priority patent/CA3128078A1/fr
Priority to CA3128660A priority patent/CA3128660A1/fr
Priority to CA3132188A priority patent/CA3132188A1/fr
Priority to EP21876820.8A priority patent/EP4225923A1/fr
Priority to CA3173429A priority patent/CA3173429A1/fr
Priority to UY0001039464A priority patent/UY39464A/es
Priority to PCT/CA2021/051419 priority patent/WO2022073131A1/fr
Priority to TW110137629A priority patent/TW202222821A/zh
Priority to CN202180083258.0A priority patent/CN116710129A/zh
Publication of CA3113094A1 publication Critical patent/CA3113094A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Physics & Mathematics (AREA)
CA3113094A 2020-10-09 2021-03-23 Compositions et methodes de prevention et/ou de traitement de la covid-19 Pending CA3113094A1 (fr)

Priority Applications (12)

Application Number Priority Date Filing Date Title
CA3116284A CA3116284A1 (fr) 2020-10-09 2021-04-23 Compositions et methodes de prevention et/ou de traitement de la covid-19
CA3116932A CA3116932A1 (fr) 2020-10-09 2021-04-30 Compositions et methodes de prevention et/ou de traitement de la covid-19
CA3118329A CA3118329A1 (fr) 2020-10-09 2021-05-12 Compositions et methodes de prevention et/ou de traitement de la covid-19
CA3128078A CA3128078A1 (fr) 2020-10-09 2021-08-09 Compositions et methodes de prevention et/ou de traitement de la covid-19
CA3128660A CA3128660A1 (fr) 2020-10-09 2021-08-19 Compositions et methodes de prevention et/ou de traitement de la covid-19
CA3132188A CA3132188A1 (fr) 2020-10-09 2021-09-28 Compositions et methodes de prevention et/ou de traitement de la covid-19
CN202180083258.0A CN116710129A (zh) 2020-10-09 2021-10-08 用于预防和/或治疗covid-19的组合物和方法
EP21876820.8A EP4225923A1 (fr) 2020-10-09 2021-10-08 Compositions et méthodes pour prévenir et/ou traiter la covid-19
CA3173429A CA3173429A1 (fr) 2020-10-09 2021-10-08 Compositions et methodes pour prevenir et/ou traiter la covid-19
UY0001039464A UY39464A (es) 2020-10-09 2021-10-08 Composiciones y métodos para la prevención y/o tratamiento de la covid-19
PCT/CA2021/051419 WO2022073131A1 (fr) 2020-10-09 2021-10-08 Compositions et méthodes pour prévenir et/ou traiter la covid-19
TW110137629A TW202222821A (zh) 2020-10-09 2021-10-08 用於預防及/或治療covid-19之組合物及方法

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CA3,096,009 2020-10-09
CA3096009A CA3096009A1 (fr) 2020-10-09 2020-10-09 Compositions et methodes de prevention et/ou de traitement de la covid-19
CA3107232A CA3107232A1 (fr) 2020-10-09 2021-01-26 Compositions et methodes de prevention et/ou de traitement de la covid-19
CA3,107,232 2021-01-26

Publications (1)

Publication Number Publication Date
CA3113094A1 true CA3113094A1 (fr) 2022-04-09

Family

ID=81077406

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3113094A Pending CA3113094A1 (fr) 2020-10-09 2021-03-23 Compositions et methodes de prevention et/ou de traitement de la covid-19

Country Status (1)

Country Link
CA (1) CA3113094A1 (fr)

Similar Documents

Publication Publication Date Title
US20210220467A1 (en) Nucleic acid vaccines
US20190192653A1 (en) Compositions and methods for tolerizing cellular systems
AU2014329452B2 (en) Polynucleotides encoding low density lipoprotein receptor
WO2016164762A1 (fr) Polynucléotides codant pour des mutants, au niveau des domaines egf-a et intracellulaire, du récepteur des lipoprotéines basse densité et et leurs procédés d'utilisation
EP3307305A1 (fr) Vaccins adaptatifs ciblés
AU2014329452A1 (en) Polynucleotides encoding low density lipoprotein receptor
AU2014239589A1 (en) Compositions and methods of altering cholesterol levels
CA3132188A1 (fr) Compositions et methodes de prevention et/ou de traitement de la covid-19
WO2023137550A1 (fr) Compositions et méthodes pour prévenir et/ou traiter la covid-19
CA3118329A1 (fr) Compositions et methodes de prevention et/ou de traitement de la covid-19
CA3113094A1 (fr) Compositions et methodes de prevention et/ou de traitement de la covid-19
CA3116284A1 (fr) Compositions et methodes de prevention et/ou de traitement de la covid-19
CA3116932A1 (fr) Compositions et methodes de prevention et/ou de traitement de la covid-19
CA3128078A1 (fr) Compositions et methodes de prevention et/ou de traitement de la covid-19
CA3107232A1 (fr) Compositions et methodes de prevention et/ou de traitement de la covid-19
CA3146392A1 (fr) Compositions et methodes de prevention et/ou de traitement de la covid-19
CA3146411A1 (fr) Compositions et methodes de prevention et/ou de traitement de la covid-19
CA3154578A1 (fr) Compositions et methodes de prevention et/ou de traitement de la covid-19
WO2024073848A1 (fr) Compositions et méthodes pour prévenir et/ou traiter la covid-19